Potassium Phosphates Injection, Solution, Concentrate
NDC Package 68462-786-25

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Potassium Phosphates injection is indicated as a source of phosphorus:•in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated.•for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. This formulation utilizes a injection, solution, concentrate delivery system. Marketed by Glenmark Pharmaceuticals Inc., Usa, this product is identified by NDC 68462-786 and is authorized under FDA application ANDA220373.

Identification & Billing

NDC Package Code
68462-786-25
Package Description
25 VIAL, SINGLE-DOSE in 1 CARTON / 5 mL in 1 VIAL, SINGLE-DOSE (68462-786-05)
Product Code
68462-786
11-Digit Billing Format
68462078625
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 1928567 - potassium phosphates (phosphorus 15 MMOL / potassium 22 MEQ) in 5 ML Injection
  • RxCUI: 1928567 - 5 ML dibasic potassium phosphate 236 MG/ML / monobasic potassium phosphate 224 MG/ML Injection
  • RxCUI: 1928567 - 5 ML Dibasic K+ phosphate 236 MG/ML / Monobasic K+ phosphate 224 MG/ML Injection
  • RxCUI: 1928567 - 5 ML Dibasic Pot phosphate 236 MG/ML / Monobasic Pot phosphate 224 MG/ML Injection
  • RxCUI: 1928567 - phosphorus 15 MMOL / potassium 22 MEQ per 5 ML Injection

Clinical Specifications

Proprietary Name
Potassium Phosphates
Non-Proprietary Name
Potassium Phosphates
Substance Name
Dibasic Potassium Phosphate; Monobasic Potassium Phosphate
Dosage Form
Injection, Solution, Concentrate - A sterile preparation for parenteral use which, upon the addition of suitable solvents, yields a solution conforming in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Potassium phosphates injection is indicated as a source of phosphorus:•in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated.•for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated.

Regulatory & Marketing

Labeler Name
Glenmark Pharmaceuticals Inc., Usa
Product Type
Human Prescription Drug
FDA Application #
ANDA220373
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-12-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68462-786-25 identifies a specific commercial package of 25 vial, single-dose in 1 carton / 5 ml in 1 vial, single-dose (68462-786-05) of Potassium Phosphates, a human prescription drug labeled by Glenmark Pharmaceuticals Inc., Usa. This injection, solution, concentrate is formulated for intravenous use and contains dibasic potassium phosphate; monobasic potassium phosphate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glenmark Pharmaceuticals Inc., Usa on March 12, 2026. The current certification is valid through December 31, 2027.

How is this Glenmark Pharmaceuticals Inc., Usa product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68462078625. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68462-786-25
11-Digit CMS (5-4-2)
68462-0786-25

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.